Tesamorelin 20mg Peptide

Tesamorelin is a growth hormone releasing hormone (GHRH) analogue: standard GHRH carrying an additional trans-3-hexanoic acid group. In 2010 it became the newest peptide to win FDA approval, in its case for use in HIV-associated lipodystrophy. Beyond that indication it has been investigated for its ability to improve peripheral nerve regeneration and as a potential intervention in mild cognitive impairment (MCI), the state that precedes dementia.

Tesamorelin is a stabilised analogue of human growth hormone releasing hormone, built on the full 44 residue sequence rather than the 29 residue fragment used by sermorelin, and carrying a trans-3-hexenoyl group attached at the N-terminus. That acyl group is the defining modification: it protects the vulnerable N-terminal region from dipeptidyl peptidase-4, which cleaves native GHRH near position 2 and destroys the determinant required for receptor activation.

At the receptor it is a full agonist at the GHRH receptor on pituitary somatotrophs, signalling through Gs and cyclic AMP to trigger both release and synthesis of growth hormone. Because it works through the physiological pathway, secretion remains pulsatile and remains subject to somatostatin tone and to negative feedback from circulating insulin-like growth factor 1, which is the pharmacological distinction from administering growth hormone itself.

The reason it became an approved medicine rather than a research compound is a specific downstream observation. Growth hormone has a preferential lipolytic effect on visceral adipose tissue, and raising endogenous growth hormone through the GHRH receptor reduced visceral fat in people with HIV-associated lipodystrophy while leaving subcutaneous fat comparatively less affected. That selectivity between fat compartments, rather than weight reduction as such, is what the approved indication rests on.

Treating HIV-associated lipodystrophy is the primary use, and the FDA approval granted in 2010 was specific to that condition. The peptide has been found to reduce adiposity by close to 20%[1]. Research puts it at roughly four times more effective at reducing adiposity than all other available therapies combined[2].

People with HIV carry an increased risk of developing cardiovascular disease. Tesamorelin has been shown to reduce triglyceride levels, total cholesterol and non-HDL-C. A 15% reduction in visceral adipose tissue achieved with tesamorelin correlates with a 50 mg fall in triglyceride levels[3], [4].

Recent evidence associates HAART with growth hormone deficiency: roughly one third of HIV patients taking HAART are GH deficient[5]. Raising GH levels with tesamorelin is both safer and more effective than administering exogenous GH.

Peripheral nerve damage can follow injury, diabetes or surgical intervention. Research suggests that therapies built on manipulating growth hormone may improve the outcome of such injuries[6]. Tesamorelin is currently the leading candidate among them, partly because the FDA approval is already in hand.

A large randomized, double-blind, placebo-controlled study at the University of Washington School of Medicine suggests that tesamorelin and other GHRH analogues may act on dementia by raising GABA levels in the brain and lowering myo-inositol levels[7].

Sermorelin demonstrated that the first 29 residues of GHRH carry essentially full receptor activity, so a shorter peptide is sufficient for agonism. Tesamorelin nonetheless uses the full 44 residue sequence.

The choice reflects a different design goal. Sermorelin was developed principally as a short-acting diagnostic and paediatric therapeutic, where rapid clearance is acceptable or even useful. Tesamorelin was developed for sustained daily use in a chronic metabolic indication, where stability and a well-characterised full-length molecule mattered more than synthetic economy.

The functional modification is at the N-terminus in both cases, because that is where the enzymatic vulnerability lies. Sermorelin leaves it unprotected. Tesamorelin caps it with an acyl group, and the modified GRF and CJC-1295 constructs protect it with amino acid substitutions instead.

Visceral adipose tissue and subcutaneous adipose tissue are metabolically different. Visceral fat drains to the portal circulation and is more strongly associated with metabolic and cardiovascular risk, which is why a treatment that reduces it preferentially is of clinical interest independently of total weight.

Growth hormone is preferentially lipolytic at visceral depots, and raising endogenous growth hormone through the GHRH receptor exploits that selectivity. The approved indication rests on this compartment-specific effect rather than on weight reduction, which is a materially different claim from the one made for incretin agents.

Reading across from tesamorelin to weight-loss compounds, or the reverse, therefore misrepresents both. They act on different tissue compartments through unrelated mechanisms.

Tesamorelin is approved in the United States for reduction of excess visceral abdominal fat in people with HIV and lipodystrophy. That indication is narrow and specific, and the trial populations that supported it were correspondingly specific.

Approval for one indication in one population is not evidence for use in others. Later work has examined hepatic fat and broader body composition endpoints, but these extend the evidence base rather than extending the approval.

Material supplied for laboratory work is for in-vitro research use only, is not a medicine, and nothing summarised here is guidance for use in humans or animals.

At 44 residues plus an acyl modification, tesamorelin is a large peptide by the standards of this catalogue, and its size makes full sequence confirmation more demanding than mass confirmation alone. It contains a methionine, so oxidised variants adding 16 daltons are a plausible related substance.

The N-terminal hexenoyl group is the defining feature of the molecule. A des-acyl species is unmodified GHRH(1-44), which is a different and far less stable molecule, and the mass difference makes the two distinguishable on a certificate that reports it.